AZN - AstraZeneca PLC
38.76 0.00 (0.00%)
After hours: 4:16PM EDT
| Previous Close | 38.85 |
| Open | 39.08 |
| Bid | 34.00 x 4000 |
| Ask | 39.70 x 1200 |
| Day's Range | 38.72 - 39.08 |
| 52 Week Range | 28.84 - 39.76 |
| Volume | 4,979,381 |
| Avg. Volume | 3,904,168 |
| Market Cap | 102.555B |
| Beta | 0.61 |
| PE Ratio (TTM) | 36.74 |
| EPS (TTM) | 1.05 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (3.60%) |
| Ex-Dividend Date | 2018-08-09 |
| 1y Target Est | 39.89 |
- Zacks Small Cap Research•yesterday
CEMI: Ethiopian Tender, Bio-Manguinhos Order Propel Q2 Product Sales. More Revenue Catalysts Emerge.
Q2 2018: Ethiopian Tender, Bio-Manguinhos Order Propel Product Sales. Product sales remain very strong, up 137% yoy and +7% from Q1 and bolstered by both of these recent contract wins (i.e. Both the DPP Zika and Chikungunya tests have received ANVISA approval.
- Zacks•4 days ago
Top Research Reports for Cisco, AstraZeneca & Enbridge
Top Research Reports for Cisco, AstraZeneca & Enbridge
- Benzinga•5 days ago
Jefferies Downgrades AstraZeneca, Sees Limited Additional Upside
With AstraZeneca stock up 12.5 percent in the past six months, Hilliker said the stock is fairly valued at this point. Jefferies had upgraded the stock to Buy back in March based on expectations that the company would be able to grow CORE EPS by 20 percent annually from 2020 to 2022 due to new product growth and expanding margins, the analyst said. With the stock up about 22 percent since his Buy call, Hilliker said additional near-term upside is likely limited.
- Market Realist•6 days ago
Analysts’ Recommendations for GlaxoSmithKline Stock
This year, analysts expect GlaxoSmithKline’s (GSK) revenue to grow 0.4% YoY (year-over-year) to ~30.3 billion British pounds from ~30.2 billion pounds, and its income margin to narrow YoY to 17.9% from 18.1%. They expect it to report EPS of 110.75 pence.
- The Wall Street Journal•7 days ago
[$$] European Corporate Roundup for Wednesday
European Corporate Roundup for Wednesday Admiral Group 1H Interim Profit Rose on Motor-Unit Growth Admiral Group PLC said Wednesday that its first-half profit rose on growth in its core U.K. motor-insurance business, despite poor weather hurting its household unit.
Market Realist•7 days agoAnalyzing Nektar Therapeutics’ Financial Performance
Nektar Therapeutics (NKTR) generated revenue of $1.09 billion in the second quarter compared to $34.59 million in the second quarter of 2017.
- Market Realist•7 days ago
What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2
GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products. In the second quarter, the segment’s revenue grew 3% YoY (year-over-year) at constant exchange rates to ~1.8 billion British pounds, as shown in the chart below. GlaxoSmithKline bought out Novartis’s (NVS) stake in the companies’ consumer healthcare joint venture on June 1.
- Benzinga•8 days ago
Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech
Allakos Inc (NASDAQ: ALLK ), a clinical-stage biotech company developing treatment for various eosinophil and mast-cell related diseases, offered 7.13 million shares in an IPO at $18 per share. The Analysts ...
Market Realist•8 days agoCan Victoza Continue to Boost Novo Nordisk’s Revenue Growth?
Novo Nordisk’s (NVO) Victoza generated revenues of 11.7 billion Danish kroner in the first half of 2018 compared to 11.5 billion Danish kroner in the first half of 2017, a ~2% YoY (year-over-year) growth and a ~12% YoY growth in local currencies.
- Market Realist•8 days ago
Analyzing GlaxoSmithKline’s Revenue Trends
In the second quarter, GlaxoSmithKline’s (GSK) revenue was nearly flat YoY (year-over-year) at 7.3 billion British pounds, reflecting 4% growth at constant exchange rates offset by a 4% impact by foreign exchange. The pound strengthened, weakening GSK’s revenue. The chart below shows GlaxoSmithKline’s revenue since the first quarter of 2017.
- Zacks•8 days ago
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
- Zacks•11 days ago
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
- Reuters•14 days ago
AstraZeneca settles Texas drug lawsuits for $110 mln
Drugmaker AstraZeneca has agreed to pay $110 million to settle two lawsuits brought by the state of Texas claiming that it fraudulently marketed the antipsychotic drug Seroquel and Crestor for high cholesterol. The largest settlement, totalling $90 million, resolves allegations the drugmaker encouraged doctors to use Seroquel for unapproved uses. A second settlement for $20 million covers allegations it misrepresented the benefits of Crestor.
- Bloomberg•14 days ago
AstraZeneca to Pay $110 Million to Settle Texas Drug Suits
AstraZeneca Plc agreed to pay $110 million to settle a Texas claim alleging that the company cheated the state’s Medicaid program by fraudulently marketing two medications, according to the state’s attorney general office. Texas claimed the drugmaker had targeted the state’s Medicaid program by urging doctors to prescribe its antipsychotic drug Seroquel for unapproved treatments, and that it had misrepresented Crestor, a cholesterol fighter, as superior to other statins. Texas claimed AstraZeneca promoted Seroquel to Medicaid providers who primarily treated children and adolescents when it wasn’t approved as safe or effective for that population.
- Market Realist•14 days ago
Examining Pfizer’s Performance by Segment in Q2 2018
As we discussed earlier, Pfizer’s (PFE) business is separated into two segments: Innovative Health and Essential Health. The Innovative Health segment contributes over 61.4% of Pfizer’s total revenue. This rise included a 5% rise in operating revenue and a 3% favorable impact of foreign exchange.
- Zacks•14 days ago
Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.
- Investor's Business Daily•18 days ago
Tesaro CEO Says Its Drug 'Will Get There' — Analysts Strongly Disagree
Tesaro stock crashed to a four-year low Friday after the biotech cut its 2018 outlook and analysts suggested its key drug, Zejula, is struggling to gain traction in the U.S.
- Bloomberg•19 days ago
To Get the Latest Drugs, Head to China
It’s been less than a year since Beijing cut back red tape on drug approvals and already Chinese patients can expect to get some breakthrough medicines before Americans. Britain’s AstraZeneca Plc will bring its newest anemia treatment to pharmacies in Shanghai and Beijing about a year before it’s available in U.S. cities. “Twenty years from now, China’s going to have a market that’s comparable, or possibly bigger, than the U.S.,” said Daniel Mahony, a health-care fund manager with Polar Capital LLP in London.
Market Realist•19 days agoHow Merck’s Oncology Drugs Have Performed
In the second quarter of 2018, Merck’s (MRK) Emend generated revenues of $148.0 million compared to $143.0 million in the second quarter of 2017, which reflected ~3% year-over-year (or YoY) growth and ~18% growth sequentially. In Q2 2018, in the US and international markets (outside the US markets), Emend generated revenues of $89.0 million and $59.0 million, respectively, compared to $83.0 million and $60.0 million in Q2 2017.
Market Realist•19 days agoHow Is Merck’s Diabetes and Women’s Health Business Positioned?
In the second quarter of 2018, Merck’s (MRK) Januvia and Janumet generated revenues of $949 million and $585.0 million, respectively. In Q2 2018, Januvia revenues remained flat compared to Q2 2017 while Janumet revenues witnessed ~4% YoY growth. In the second quarter of 2018, both Januvia and Janumet witnessed ~8% sequential growth.
- American City Business Journals•20 days ago
The opioid drug that addicts don't like could be approved next spring
In studies, Nektar found opioid abusers rated its experimental, pain-killing opioid, which takes longer to reach the brain, as less likable than oxycodone.
- Market Realist•20 days ago
Eli Lilly’s Q2 2018 Earnings: How Did Its Segments Perform?
Eli Lilly & Co. (LLY) reports its revenues under two segments—Human Pharmaceuticals and Elanco, its animal health business. The chart below compares the segments’ revenues since the first quarter of 2017.
- Zacks•22 days ago
Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT
Let's see how pharma/biotech stocks are poised ahead of their scheduled results on Jul 31.
- Thomson Reuters StreetEvents•23 days ago
Edited Transcript of AZN.L earnings conference call or presentation 26-Jul-18 11:30am GMT
Q2 2018 AstraZeneca PLC Earnings Call
- Zacks•25 days ago
Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod
Earnings are in focus this week with Lilly (LLY), Allergan (AGN) and Glaxo (GSK) delivering strong Q2 numbers. AbbVie (ABBV) gains FDA approval for Elagolix.
